ZARXIO® (filgrastim-sndz) Has Exceptional Coverage Under National and Regional Plans

ZARXIO has the most unrestricted medical and pharmacy benefit coverage in the G-CSF class1-3*†

Select your state
Select your coverage type
Please see table below for updated coverage
based on your selection
Select your coverage type
Select your benefit type
Find my ZARXIO Coverage!
Please see table below for updated coverage
based on your selection
ZARXIO Top 10 Plans
Learn more about the value of Sandoz biosimilars Visit to learn more about
your ZIEXTENZO® (pegfilgrastim-bmez) coverage

Most defined as a comparison to NEUPOGEN®, Granix®, RELEUKO®, and NIVESTYM® in terms of combined medical and pharmacy benefit status. Unrestricted defined as on formulary, managed to Prescribing Information, and not requiring prior authorization and step edits. Coverage defined as “Exclusive or Co-Preferred" on commercial, Medicare, health exchange plans, and pharmacy benefit managers (PBMs) on pharmacy benefit, and commercial, Medicare, and health exchange plans on medical benefit according to Managed Markets Insight & Technology (MMIT) data as of September 2019.

Source: MMIT Policy & Restriction Analytics (July 2023 data file). Covered lives % calculated using AIS lives per MMIT source.

References: 1. Data on file. Zitter Sandoz Neutropenia Commercial Pharmacy and Medical Coverage Analysis. Princeton, NJ: Sandoz Inc; 2019. 2. Short Acting Filgrastim Medical Coverage. Yardley, PA: MMIT; July 2023. 3. Short Acting Filgrastim Pharmacy Coverage. Yardley, PA: MMIT; July 2023.